The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3111686 28 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background. The mammalian target of rapamycin (mTOR) inhibitor, rapamycin, has been shown to inhibit the progression of murine lupus nephritis by virtue of its potent immunosuppressive properties. The phosphoinositol-3-kinase (PI3K)/Akt pathway is a major upstream activator of mTOR and has been implicated in the propagation of cancer and autoimmunity. However, the activation status of the PI3K/Akt/mTOR pathway in lupus nephritis has not been studied so far.Methods. In NZBW/F1 female mice, we examined the glomerular expression of Akt and mTOR by immunofluorescence and western blot. We also searched for specific phosphorylations of these kinases known to ensue during activation of the PI3K/Akt/mTOR pathway. In parallel, we examined the therapeutic role of rapamycin either before or after the development of overt lupus nephritis.Results. We found that in untreated mice, as opposed to healthy controls, Akt and mTOR were over-expressed and phosphorylated at key activating residues. Rapamycin prolonged survival, maintained normal renal function, normalized proteinuria, restored nephrin and podocin levels, reduced anti-dsDNA titres, ameliorated histological lesions, and reduced Akt and mTOR glomerular expression activation.Conclusions. These results suggest that: (i) the PI3K/Akt/mTOR pathway is upregulated in murine lupus nephritis, thus justifying treatment with rapamycin; (ii) rapamycin not only blocks mTOR but also negatively regulates the PI3K/Akt/mTOR pathway; and (iii) rapamycin is an effective treatment of murine lupus nephritis. Examination of the PI3K/Akt/mTOR pathway may offer new insights into the pathogenesis of lupus nephritis in humans and may lead to more individualized and less toxic treatment. © The Author 2010. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Έτος δημοσίευσης:
2011
Συγγραφείς:
Stylianou, K.
Petrakis, I.
Mavroeidi, V.
Stratakis, S.
Vardaki, E.
Perakis, K.
Stratigis, S.
Passam, A.
Papadogiorgaki, E.
Giannakakis, K.
Nakopoulou, L.
Daphnis, E.
Περιοδικό:
Nephrology Dialysis Transplantation
Τόμος:
26
Αριθμός / τεύχος:
2
Σελίδες:
498-508
Λέξεις-κλειδιά:
actin; creatinine; mammalian target of rapamycin; nephrin; phosphatidylinositol 3 kinase; podocin; protein kinase B; rapamycin, animal cell; animal experiment; animal model; animal tissue; antibody titer; article; competitive inhibition; controlled study; creatinine blood level; down regulation; enzyme activation; enzyme activity; female; glomerulus; histopathology; immunofluorescence; kidney function; kidney parenchyma; lupus erythematosus nephritis; molecular dynamics; mouse; nonhuman; overall survival; pathogenesis; priority journal; protein expression; protein phosphorylation; proteinuria; upregulation; Western blotting, Animals; Down-Regulation; Female; Immunosuppressive Agents; Lupus Nephritis; Mice; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Up-Regulation
Επίσημο URL (Εκδότης):
DOI:
10.1093/ndt/gfq496
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.